Skip to content

Value of Adding T2 Mapping Routine MRI in Assessment of Knee Articular Cartilage Early Osteoarthritis

Value of Adding T2mapping Sequence to Routine MRI Protocol in Assessment of Knee Articular Cartilage in Early Osteoarthritis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07316257
Acronym
T2 mapping OS
Enrollment
70
Registered
2026-01-05
Start date
2026-01-01
Completion date
2027-02-01
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

OA, OA Knee, Osteearthritis

Brief summary

This work aims at elucidating the role of MRI complementary T2 mapping in assessment of the articular knee cartilage for improving sensitivity of detection of early stage of osteoarthritis

Detailed description

Osteoarthritis (OA) is one of the most common degenerative joint diseases, affecting more than 500 million people worldwide (1), causing joint pain and stiffness, and negatively affecting quality of life . The knee is the most commonly affected joint, followed by the hand and hip (1). It is important clinically to diagnose osteoarthritis in its early stages to prevent its inevitable progression (2) Routine MR imaging sequences used in the identification of knee osteoarthritis can assess articular cartilage morphology, but despite its accuracy for identifying deep hyaline cartilage defects which are considered irreversible cartilage degeneration with limited treatment options, it lacks sufficient sensitivity for early cartilage changes and low-grade chondral lesions which are the reversible stages for the potential alteration of the osteoarthritis progression(2). T2 mapping of hyaline cartilage is an imaging technique for the qualitative and quantitative detection of the cartilage providing convincing color mapping and quantitative detection of the cartilage mainly regarding architecture and changes in water content, proteoglycan, and collagen matrix ultra-structure associated with early cartilage degeneration(3). T2 mapping is a time constant describing the rate at which energy transfer occurs between water protons in a magnetic field (spin-spin interactions), leading to signal dephasing. In normal healthy articular cartilage, water protons are largely bound in place by a well-organized matrix of collagen fibers, allowing for rapid dephasing, and therefore low T2 values are seen(4). However, in osteoarthritic articular cartilage, the collagen fibers become disorganized, and there are more mobile water protons, resulting in high T2 values. (4).

Interventions

DEVICEMRI

Device that use coil to image asses the articular cartilage of the knee

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* patients with clinical evidence of osteoarthritis

Exclusion criteria

* • contraindications for MRI such as claustrophobia, heart pacemaker and ferromagnetic implants * patients in which the misaligned images or distortions due to motion artifacts made the interpretation of the MRI unreliable. * Patients with previous knee operation

Design outcomes

Primary

MeasureTime frameDescription
This work aims at elucidating the role of MRI complementary T2 mapping to measure the changes in T2 relaxation time of the articular knee cartilage in healthy group which there number will be 28 and pateints with early osteoarthritis there number 28baselineto detect the value of adding T2 mapping to routine MRI in assessment of the articular cartilage in knee osteoarthritis

Secondary

MeasureTime frameDescription
This work aims at quantitive stratification of osteoarthrtic changes and its impact on treatementbaselineto detect the value of adding T2 mapping to routine MRI in assessment of knee articular cartilage in knee osteoarthritis

Contacts

Primary ContactShrouk Mohamed Gad, MSC
shroukgad194@gmail.com+201028565525
Backup Contactzahraa sayed hassan, MD
zahra.art@aun.edu.eg+201026816205

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026